Eita Joki, Hiroyuki Kato, Hiroki Tani, Yukio Asano, Masahiro Ito, Satoshi Arakawa, Masahiro Shimura, Daisuke Koike, Takayuki Ochi, Kenshiro Kamio, Toki Kawai, Hironobu Yasuoka, Takahiko Higashiguchi, Yoshiki Kunimura, Kazuma Horiguchi, Hidetoshi Nagata, Yuka Kondo, Harunobu Sato, Yutaro Kato, Tsunekazu Hanai, Akihiko Horiguchi
Gan to kagaku ryoho. Cancer & chemotherapy, 50(8) 933-936, Aug, 2023
We report a case of a patient with sigmoid colon cancer and multiple liver metastases who underwent hepatectomy after chemotherapy and pathological results showed complete remission. However, after chemotherapy was discontinued, the patient developed a local recurrence of the liver metastasis and underwent rehepatectomy. The patient came to our hospital with lower abdominal pain. Colonoscopy revealed a circumferential type Ⅱ, well-differentiated adenocarcinoma. Laparoscopic sigmoidectomy with lymph node dissection was performed. Postoperative CT scan showed multiple liver metastases at S5, S7, and S8. 11 cycles of bevacizumab plus modified FOLFOX(mFOLFOX)were subsequently performed. The liver metastases shrank at all sites, and the patient underwent right hepatectomy. The resected specimen was considered to be in complete remission, with no evidence of viable malignant cells. Postoperatively, bevacizumab plus mFOLFOX was resumed for 6 cycles and the patient remained in remission. However, 3 months after stopping chemotherapy and 1 year and 6 months after hepatectomy, a follow-up CT scan showed local recurrence of the liver edge, and a diagnosis of local recurrence of liver metastasis was made, and a partial hepatectomy was performed. The patient is recurrence-free and resuming modified FOLFOX 9 months after surgery.